trending Market Intelligence /marketintelligence/en/news-insights/trending/_xn_9m0prdfbvlxelb3bfa2 content esgSubNav
In This List

Seattle Genetics appoints chief medical officer

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Seattle Genetics appoints chief medical officer

Seattle Genetics Inc. said May 17 that it named Roger Dansey chief medical officer.

Dansey was most recently senior vice president at Merck & Co. Inc., where he was therapeutic area head for late-stage oncology. Before joining Merck, he worked at Gilead Sciences Inc. as vice president of oncology clinical research.

Dansey replaces Jonathan Drachman, who will continue to work with Seattle Genetics as a strategic adviser for innovation.

Bothell, Wash.-based Seattle Genetics is a biotechnology company that develops and sells targeted cancer therapies.